Biotech Archives - Page 691 of 733

1 minute read

Analyst Sees Deteriorated Treatment Effect Of Blueprint’s Much Awaited Mastocytosis Data

August 17, 2:56 PM

Earlier today, Blueprint Medicines Corporation (NASDAQ: BPMC) released the long-awaited pivotal PIONEER dataset in Indolent Systemic Mastocytosis (ISM). The topline data indicates that…

BPMC

2 minute read

Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022

By Vandana Singh

August 17, 2:52 PM

As the U.S. plans to get out of the crisis phase, the Biden administration said it would stop buying…

BNTX

1 minute read

Sanofi Earns Price Target Cut After Stopping Breast Cancer Drug Trial

By Vandana Singh

August 17, 2:28 PM

Sanofi SA (NASDAQ:SNY) discontinued the development of its oral SERD amcenestrant following a negative interim analysis of the AMEERA-5…

PFE

3 minute read

Bluebird Bio PR Announces FDA Approval Of ZYNTEGLO

By Bill Haddad

August 17, 2:07 PM

ZYNTEGLO offers potentially curative benefit across ages and genotypes, through the achievement of durable transfusion independence and normal or near normal total hemoglobin levels Management team to host conference

BLUE

1 minute read

bluebird bio Says List Price Of Newly-Approved Gene Therapy Is At $2.8M

By Michael Horton

August 17, 1:48 PM

-Reuters

BLUE

1 minute read

‘Bluebird wins U.S. approval for a gene therapy to treat patients with a rare blood disorder’ -STAT

By Michael Horton

August 17, 1:39 PM

https://www.statnews.com/2022/08/17/bluebird-wins-fda-approval-for-gene-therapy-for-beta-thalassemia/?utm_content=bufferba14a&utm_medium=social&utm_source=twitter&utm_campaign=twitter_organic

BLUE

1 minute read

CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks

By Vandana Singh

August 17, 12:10 PM

CSL (OTC:CSLLY) announced topline Phase 3 results for garadacimab (CSL312) for hereditary angioedema (HAE). HAE is a rare genetic condition that…

CSLLY

2 minute read

Ambrx Announces Abrupt Leadership Change, Discuses Pipeline Review

By Vandana Singh

August 17, 11:20 AM

Kate Hermans has taken over the reins of Ambrx Biopharma Inc (NASDAQ:AMAM) as interim CEO following the abrupt departure of Feng Tian,…

AMAM

1 minute read

As The Only Monkeypox Maker Struggles, This Small Cap Plans To Develop Novel Shot

By Vandana Singh

August 17, 11:11 AM

Blue Water Vaccines Inc (NASDAQ: BWV)

BVNKF

1 minute read

RedHill Shares Gain As European Commission Grants Orphan Drug Status To NTM Infections Candidate

By Ragothaman Srinivasan

August 17, 10:55 AM

The European Commission has granted Orphan Drug Designation to RedHill Biopharma’s (NASDAQ: RDHL) lead asset RHB-204 for the treatment of nontuberculous mycobacteria (NTM) disease.

RDHL